ConductScience.org, home

Paper28958502

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.

Wu YL and 17 others. Lancet Oncol, 2017. Cited by 998 papers, by iCite.

Cite this record

ConductScience Library. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Papers, record 28958502. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28958502

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.
PubMed
Journal
Lancet Oncol
PubMed
Year
2017
PubMed
Publication types
Clinical Trial, Phase III, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial
PubMed
Citations, by iCite
998
iCite
Relative citation ratio, by iCite
32.2
iCite
Revised in PubMed
2022-04-10
PubMed

Authors18

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Wu YLYi-Long
2Cheng YYing
3Zhou XXiangdong
4Lee KHKi Hyeong
5Nakagawa KKazuhiko
6Niho SSeiji
7Tsuji FFumito
8Linke RRolf
9Rosell RRafael
10Corral JJesus
11Migliorino MRMaria Rita
12Pluzanski AAdam
13Sbar EIEric I
14Wang TTao
15White JLJane Liang
16Nadanaciva SSashi
17Sandin RRickard
18Mok TSTony S

Source PubMed

Download CSV of authors

Topics22

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Carcinoma, Non-Small-Cell LungMajor topic
Genes, erbB-1Major topic
Lung NeoplasmsMajor topic
QuinazolinesMajor topic
QuinazolinonesMajor topic
Adult
Aged
Confidence Intervals
Disease-Free Survival
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Gefitinib
Humans
Kaplan-Meier Estimate
Male
Maximum Tolerated Dose
Middle Aged
Mutation
Prognosis
Survival Analysis
Treatment Outcome

Source PubMed

Download CSV of topics

Trials7

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT01774721ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.Derived from the trialYesClinicalTrials.gov
NCT04339829An Open Label, Multicenter, Phase II Study of Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain MetastasesBackgroundClinicalTrials.gov
NCT04358562Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With GefitinibResultsClinicalTrials.gov
NCT04619563A Trial of Anlotinib Combined With Docetaxel in EGFR Mutations Advanced Non Small Cell Lung Cancer PatientsBackgroundClinicalTrials.gov
NCT04640870The Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients With Advanced EGFR Mutation-positive Non-small Cell Lung Cancer Treated With AfatinibBackgroundClinicalTrials.gov
NCT05271916First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R MutationsBackgroundClinicalTrials.gov
NCT06643416Efficacy and Safety of Add-on Timolol for EGFR-TKI and ALK-TKI Induced ParonychiaBackgroundClinicalTrials.gov

Download CSV of trials

Comments and corrections5

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn PapersSource
Comment in28958503Treatment choice in EGFR-mutant non-small-cell lung cancer.https://conductscience.org/library/papers/28958503PubMed
Comment in29304361Dacomitinib in NSCLC: a positive trial with little clinical impact.https://conductscience.org/library/papers/29304361PubMed
Comment in29304363Dacomitinib in NSCLC: a positive trial with little clinical impact - Authors' reply.https://conductscience.org/library/papers/29304363PubMed
Comment in29780702Dacomitinib in EGFR-positive non-small cell lung cancer: an attractive but broken option.https://conductscience.org/library/papers/29780702PubMed
Comment in29780706The evolving first-line treatment of advanced non-small cell lung cancer harbouring epidermal growth factor receptor mutations.https://conductscience.org/library/papers/29780706PubMed

Download CSV of comments and corrections

Cited by663

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 998 citations.

PMIDTitleJournalYearIn PapersSource
42985096Optimizing first-line therapy for advanced EGFR-mutated NSCLC: a patient-centered approach for low- and middle- income countries.Front Oncol2026https://conductscience.org/library/papers/42985096PubMed
42894004Oncogenic mutations in non-small cell lung cancer: from molecular mechanisms to clinical practice.Signal Transduct Target Ther2026https://conductscience.org/library/papers/42894004PubMed
42871070Dacomitinib With or Without Dose Titration in Treatment-Naive Advanced EGFR-Mutated NSCLC - Primary Analysis of the ATORG-003 Phase 2 Trial.JTO Clin Res Rep2026https://conductscience.org/library/papers/42871070PubMed
42799075Traditional Chinese medicine reprograms the tumor microenvironment to overcome EGFR-TKI resistance: mechanisms and therapeutic perspectives.Front Pharmacol2026https://conductscience.org/library/papers/42799075PubMed
42734867
Comparative efficacy and safety of first, second, and third-generation EGFR tyrosine kinase inhibitors in treatment-naïve EGFR-mutant advanced non-small cell lung cancer: a systematic review and network meta-analysis of randomized controlled trials.
J Egypt Natl Canc Inst2026https://conductscience.org/library/papers/42734867PubMed
42719457Integrating clinical outcomes with molecular simulations to guide the selection of non-classical EGFR-TKIs: A comprehensive analysis and development of treatment strategies.Exp Ther Med2026https://conductscience.org/library/papers/42719457PubMed
42611130"What really works for us?" exploring therapeutic strategies for non-small cell lung cancer: an umbrella review of systematic reviews and meta-analyses.Clin Transl Oncol2026https://conductscience.org/library/papers/42611130PubMed
42602055
Treatment prioritization of chemotherapy-anchored regimens after EGFR-TKI failure in EGFR-mutant NSCLC: a systematic review, pairwise meta-analysis and Bayesian network meta-analysis with probabilistic multi-criteria decision analysis.
Front Immunol2026https://conductscience.org/library/papers/42602055PubMed
42588620Targeting Classical EGFR Mutations in Lung Cancer: Twenty Years of Progress and Beyond.Cancers (Basel)2026https://conductscience.org/library/papers/42588620PubMed
42586967Mefatinib versus gefitinib as a first-line treatment for EGFR-mutated non-small cell lung cancer: a randomized, double-blind, multicenter phase III study.Signal Transduct Target Ther2026https://conductscience.org/library/papers/42586967PubMed
42528591Research progress of small molecule targeted drugs for non-small cell lung cancer.Front Oncol2026https://conductscience.org/library/papers/42528591PubMed
42444976First-line third-generation EGFR-TKIs for advanced EGFR-mutated non-small cell lung cancer: a systematic review and network meta-analysis of randomized controlled trials.J Thorac Dis2026https://conductscience.org/library/papers/42444976PubMed
42435178Targeting Lung Cancer Metabolism: Therapeutic Opportunities and Challenges.Adv Exp Med Biol2026https://conductscience.org/library/papers/42435178PubMed
42420595Opportunities and challenges in the development of evolving EGFR inhibitors to overcome EGFR TKIs resistance.Acta Pharmacol Sin2026https://conductscience.org/library/papers/42420595PubMed
42369726Clinical characteristics and outcomes of advanced EGFR-mutated NSCLC treated with 45 or 30 mg starting doses of dacomitinib: a retrospective multicenter analysis.Ther Adv Med Oncol2026https://conductscience.org/library/papers/42369726PubMed
42352924Resistance to EGFR Inhibitors in NSCLC: Mechanistic Insights and Emerging Therapies.Int J Mol Sci2026https://conductscience.org/library/papers/42352924PubMed
42317338Efficacy and mechanisms of immune checkpoint inhibitors in late-stage EGFR-mutated non-small cell lung cancer following targeted therapy resistance.Front Immunol2026https://conductscience.org/library/papers/42317338PubMed
42315733Ocular toxicities associated with anticancer drug therapy in Asian patients: a literature review and practical management recommendations for non-ophthalmologic settings.Int J Clin Oncol2026https://conductscience.org/library/papers/42315733PubMed
42305404Differential Treatment Effects by Smoking Status for NSCLC Therapies (2010-2023): A Meta-Analysis.JTO Clin Res Rep2026https://conductscience.org/library/papers/42305404PubMed
42291371Dacomitinib for EGFR-L858R-mutated non-small cell lung cancer following acquired resistance to third-generation EGFR-TKIs: a retrospective real-world study.Transl Lung Cancer Res2026https://conductscience.org/library/papers/42291371PubMed

See all 663 cited byDownload CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
EGFR1956PubTator's text mininghttps://conductscience.org/library/genes/1956

Source NCBI Gene

Download CSV of genes

Drugs3

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targetsSource
DACOMITINIBCHEMBL2105719Derived from the trial1https://conductscience.org/library/drugs/CHEMBL2105719ChEMBL
CATEQUENTINIBCHEMBL4303201Results1https://conductscience.org/library/drugs/CHEMBL4303201ChEMBL
GEFITINIBCHEMBL939Results2https://conductscience.org/library/drugs/CHEMBL939ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • References
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/28958502

GET https://conductscience.org/api/papers/v1/28958502/cited_by?page=2